{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:46:38Z","timestamp":1763729198920,"version":"3.45.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cll.2025.07.010","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T20:16:00Z","timestamp":1755116160000},"page":"657-673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent Advances in Extended Half-Life Products, Nonfactor Replacement Therapies, and Gene Therpy for the Treatment of Hemophilia"],"prefix":"10.1016","volume":"45","author":[{"given":"Prakash","family":"Vishnu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Aboulafia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cll.2025.07.010_bib1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13998","article-title":"Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres","volume":"26","author":"Soucie","year":"2020","journal-title":"Haemoph Off J World Fed Hemoph"},{"issue":"8","key":"10.1016\/j.cll.2025.07.010_bib2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"issue":"23","key":"10.1016\/j.cll.2025.07.010_bib3","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias--from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cll.2025.07.010_bib4","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/hae.13089","article-title":"Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study","volume":"22","author":"James","year":"2016","journal-title":"Haemoph Off J World Fed Hemoph"},{"issue":"3","key":"10.1016\/j.cll.2025.07.010_bib5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1055\/s-0037-1613833","article-title":"Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B","volume":"83","author":"Orstavik","year":"2000","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.cll.2025.07.010_bib6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.cll.2025.07.010_bib7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/bjh.13365","article-title":"The current status of prophylactic replacement therapy in children and adults with haemophilia","volume":"169","author":"Ljung","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.cll.2025.07.010_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.cll.2025.07.010_bib9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1055\/s-0042-1756188","article-title":"The more recent history of hemophilia treatment","volume":"48","author":"Franchini","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 6","key":"10.1016\/j.cll.2025.07.010_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hae.12466","article-title":"ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective","volume":"20","author":"Oldenburg","year":"2014","journal-title":"Haemoph Off J World Fed Hemoph"},{"issue":"21","key":"10.1016\/j.cll.2025.07.010_bib11","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2017-08-742312","article-title":"Novel approaches to hemophilia therapy: successes and challenges","volume":"130","author":"Arruda","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cll.2025.07.010_bib12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/rth2.12202","article-title":"Impact of prophylaxis on health-related quality of life of boys with hemophilia: an analysis of pooled data from 9 countries","volume":"3","author":"Usuba","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.cll.2025.07.010_bib13","unstructured":"Anderson-Cook A, Maeda J, Nelson L. Prices for and spending on specialty drugs in medicare part D and medicaid: an In-Depth analysis, Available at: https:\/\/collections.awsprod.nlm.nih.gov\/catalog\/nlm:nlmuid-101753144-pdf."},{"issue":"6","key":"10.1016\/j.cll.2025.07.010_bib15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","article-title":"A cell-based model of hemostasis","volume":"85","author":"Hoffman","year":"2001","journal-title":"Thromb Haemost"},{"issue":"7","key":"10.1016\/j.cll.2025.07.010_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM200008173430702","article-title":"High plasma levels of factor VIII and the risk of recurrent venous thromboembolism","volume":"343","author":"Kyrle","year":"2000","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cll.2025.07.010_bib17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/hae.14300","article-title":"The function of extravascular coagulation factor IX in haemostasis","volume":"27","author":"Mann","year":"2021","journal-title":"Haemoph Off J World Fed Hemoph"},{"issue":"3","key":"10.1016\/j.cll.2025.07.010_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","article-title":"Hemophilia treatment innovation: 50 years of progress and more to come","volume":"21","author":"Mannucci","year":"2023","journal-title":"J Thromb Haemost JTH"},{"issue":"8","key":"10.1016\/j.cll.2025.07.010_bib19","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2011-02-336172","article-title":"Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide","volume":"118","author":"\u00d8stergaard","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cll.2025.07.010_bib22","first-page":"365","article-title":"Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias","volume":"8","author":"Mancuso","year":"2014","journal-title":"Drug Des Dev Ther"},{"issue":"8","key":"10.1016\/j.cll.2025.07.010_bib25","first-page":"2436","article-title":"Efanesoctocog alfa: the renaissance of factor VIII replacement therapy","volume":"109","author":"Dargaud","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.cll.2025.07.010_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/17474086.2020.1716726","article-title":"The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality","volume":"13","author":"Rodriguez-Merchan","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"10.1016\/j.cll.2025.07.010_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12601","article-title":"The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B","volume":"5","author":"Sun","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"10.1016\/j.cll.2025.07.010_bib29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-07-820712","article-title":"New therapies using nonfactor products for patients with hemophilia and inhibitors","volume":"133","author":"Nogami","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cll.2025.07.010_bib30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cll.2025.07.010_bib32","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/hae.13990","article-title":"Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors","volume":"26","author":"Bowyer","year":"2020","journal-title":"Haemoph Off J World Fed Hemoph"},{"key":"10.1016\/j.cll.2025.07.010_bib33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.thromres.2023.01.007","article-title":"In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab","volume":"222","author":"Yamaguchi","year":"2023","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.cll.2025.07.010_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12561","article-title":"The effect of emicizumab and bypassing agents in patients with hemophilia - an in vitro study","volume":"5","author":"Schultz","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"10.1016\/j.cll.2025.07.010_bib35","first-page":"1334","article-title":"Emicizumab: the hemophilia A game-changer","volume":"109","author":"Alcedo Andrade","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.cll.2025.07.010_bib36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/hae.15146","article-title":"Low-dose emicizumab versus Low-\/Intermediate-Dose factor VIII secondary prophylaxis for noninhibitor haemophilia A patients with severe bleeding phenotype","volume":"31","author":"Kessakorn","year":"2025","journal-title":"Haemoph Off J World Fed Hemoph"},{"issue":"4","key":"10.1016\/j.cll.2025.07.010_bib37","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtha.2023.12.016","article-title":"FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic","volume":"22","author":"Lentz","year":"2024","journal-title":"J Thromb Haemost JTH"},{"issue":"1","key":"10.1016\/j.cll.2025.07.010_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102271","article-title":"NXT007-mediated hemostatic potential is suppressed by activated protein C-catalyzed inactivation of activated factor V","volume":"8","author":"Nakajima","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"Supplement 1","key":"10.1016\/j.cll.2025.07.010_bib41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2023-181263","article-title":"Efficacy and safety of the anti-tissue factor pathway inhibitor marstacimab in participants with severe hemophilia without inhibitors: results from the phase 3 basis trial","volume":"142","author":"Matino","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cll.2025.07.010_bib42","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"issue":"10386","key":"10.1016\/j.cll.2025.07.010_bib43","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"10.1016\/j.cll.2025.07.010_bib44","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cll.2025.07.010_bib45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024027008","article-title":"Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study","author":"Young","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.cll.2025.07.010_bib46","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.thromres.2024.01.018","article-title":"Activated protein C and free protein S in patients with mild to moderate bleeding disorders","volume":"235","author":"Mehic","year":"2024","journal-title":"Thromb Res"},{"issue":"12","key":"10.1016\/j.cll.2025.07.010_bib47","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.2023020005","article-title":"Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models","volume":"142","author":"Jiang","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cll.2025.07.010_bib48","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/bloodadvances.2023010819","article-title":"Protein S antibody as an adjunct therapy for hemophilia B","volume":"8","author":"Wilson","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.cll.2025.07.010_bib49","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/hae.14167","article-title":"Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors","volume":"27","author":"Jim\u00e9nez-Yuste","year":"2021","journal-title":"Haemoph Off J World Fed Hemoph"},{"issue":"4","key":"10.1016\/j.cll.2025.07.010_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102434","article-title":"Exploring nonreplacement therapies\u2019 impact on hemophilia and other rare bleeding disorders","volume":"8","author":"Peyvandi","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"10.1016\/j.cll.2025.07.010_bib52","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/13696998.2021.1982225","article-title":"Variation in access to hemophilia A treatments in the United States","volume":"24","author":"Margaretos","year":"2021","journal-title":"J Med Econ"},{"issue":"3","key":"10.1016\/j.cll.2025.07.010_bib53","first-page":"673","article-title":"Challenges associated with access to recently developed hemophilia treatments in routine care: perspectives of healthcare professionals","volume":"110","author":"Berger","year":"2025","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.cll.2025.07.010_bib54","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.cll.2025.07.010_bib55","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.cll.2025.07.010_bib56","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cll.2025.07.010_bib57","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear Follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cll.2025.07.010_bib58","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene therapy with fidanacogene elaparvovec in adults with hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.cll.2025.07.010_bib60","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cll.2025.07.010_bib61","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/hae.14936","article-title":"Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment","volume":"30","author":"Symington","year":"2024","journal-title":"Haemoph Off J World Fed Hemoph"},{"issue":"1","key":"10.1016\/j.cll.2025.07.010_bib64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cll.2025.07.010_bib65","unstructured":"$3.5-Million hemophilia gene therapy is world\u2019s Most expensive drug. Sci Am, 2022. Available at: https:\/\/www.scientificamerican.com\/article\/3-5-million-hemophilia-gene-therapy-is-worlds-most-expensive-drug\/ (Accessed 8 March 2025)."},{"issue":"4","key":"10.1016\/j.cll.2025.07.010_bib66","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ajh.27602","article-title":"Clinical trials update on hemophilia, VWD, and rare inherited bleeding disorders","volume":"100","author":"Jiang","year":"2025","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.cll.2025.07.010_bib67","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41392-022-01134-4","article-title":"Stem cell-based therapy for human diseases","volume":"7","author":"Hoang","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.cll.2025.07.010_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1094249","article-title":"iPSC-derived liver organoids and inherited bleeding disorders: potential and future perspectives","volume":"14","author":"Roman","year":"2023","journal-title":"Front Physiol"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271225000642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271225000642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:35:59Z","timestamp":1763728559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271225000642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0272271225000642"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2025.07.010","relation":{},"ISSN":["0272-2712"],"issn-type":[{"type":"print","value":"0272-2712"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Advances in Extended Half-Life Products, Nonfactor Replacement Therapies, and Gene Therpy for the Treatment of Hemophilia","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2025.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}